Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data by Jorge, S.E.D.C. et al.
 
Epidermal growth factor receptor (EGFR) mutations in lung cancer:
preclinical and clinical data
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Jorge, S.E.D.C., S.S. Kobayashi, and D.B. Costa. 2014.
“Epidermal growth factor receptor (EGFR) mutations in lung
cancer: preclinical and clinical data.” Brazilian Journal of Medical
and Biological Research 47 (11): 929-939. doi:10.1590/1414-
431X20144099. http://dx.doi.org/10.1590/1414-431X20144099.
Published Version doi:10.1590/1414-431X20144099
Accessed February 17, 2015 9:15:04 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13581252
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAEpidermal growth factor receptor (EGFR) mutations
in lung cancer: preclinical and clinical data
S.E.D.C. Jorge, S.S. Kobayashi and D.B. Costa
Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA, USA
Abstract
Lung cancer leads cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC), the most prevalent subtype of this
recalcitrant cancer, is usually diagnosed at advanced stages, and available systemic therapies are mostly palliative. The
probing of the NSCLC kinome has identified numerous nonoverlapping driver genomic events, including epidermal growth
factor receptor (EGFR) gene mutations. This review provides a synopsis of preclinical and clinical data on EGFR mutated
NSCLC and EGFR tyrosine kinase inhibitors (TKIs). Classic somatic EGFR kinase domain mutations (such as L858R and exon
19 deletions) make tumors addicted to their signaling cascades and generate a therapeutic window for the use of ATP-mimetic
EGFR TKIs. The latter inhibit these kinases and their downstream effectors, and induce apoptosis in preclinical models. The
aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when
gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. The benefits associated with these EGFR TKIs are
limited by the mechanisms of tumor resistance, such as the gatekeeper EGFR-T790M mutation, and bypass activation of
signaling cascades. Ongoing preclinical efforts for treating resistance have started to translate into patient care (including
clinical trials of the covalent EGFR-T790M TKIs AZD9291 and CO-1686) and hold promise to further boost the median survival
of patients with EGFR mutated NSCLC.
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Lung cancer and driver oncogenes
Lung cancer is composed of non-small-cell lung cancers
(NSCLCs; which account for over 85% of diagnosed cases),
small-cell lung cancers, and neuroendocrine tumors; and
this group of malignancies leads cancer-related mortality for
both men and women worldwide (1). In the United States
alone, in 2014, the number of new cases of lung cancer is
projected to be 224,210 and the number of deaths 159,260
(2), with this recalcitrant cancer alone accounting for a
quarter of all causes of cancer deaths (2). Worldwide, the
number of new cases exceeds a million per year (1). The
single most important risk factor for developing lung cancer
is a personal history of cigarette smoking, and genome-wide
association studies (GWAS) of patients with lung cancer
have provided strong evidence for a tobacco-dependent
susceptibility region in chromosome 15q25.1, containing
genes (CHRNA3, CHRNA5, and CHRNB4) that encode for
nicotinic acetylcholine receptors (3,4). However, up to 20%
of lung cancers in the United States occur in never-smokers,
defined as persons who have smoked fewer than 100
cigarettes in their lifetime (5). NSCLCs in never-smokers
account for the seventh most frequent cause of cancer
mortality worldwide (6). The risk factors, both environmental
and inherited, for lung cancer in never-smokers are poorly
understood, and GWAS have been relatively unrevealing of
a unifying genetic basis (5,7). As early as a decade ago, the
only available palliative options for advanced NSCLCs
included platinum-doublet cytotoxic chemotherapies, and
evidence-based treatment guidelines combined all types of
NSCLC into one single entity (8).
The last decade has uncovered knowledge on the
molecular determinants of lung cancer, and the probing of
the NSCLC kinome using next-generation sequencing
techniques has identified numerous nonoverlapping driver
genomic events (i.e., activating mutations or rearrange-
ments) involving targetable kinases, including epidermal
growth factor receptor (EGFR), anaplastic lymphoma kinase
(ALK), v-Raf murine sarcoma viral oncogene homolog B1,
V-erb-b2 erythroblastic leukemia viral oncogene homolog 2
(ERBB2), rearranged during transfection, c-ros oncogene 1,
and neurotrophic tyrosine kinase receptor type 1, among
others. Notwithstanding the gaps in knowledge of why
NSCLCs develop in never-smokers, it is now well
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diseases with a distinct biology – – compared to smoking-
related NSCLCs (where undruggable v-ki-ras2K i r s t e nr a t
sarcoma viral oncogene homolog mutations are more
frequent) – – marked by an increased incidence of targetable
mutations in oncogenes (Figure 1). The near-universal
prevalence of driver oncogenes in lung adenocarcinomas
from never-smokers truly makes these diseases putative
oncogene-driven malignancies, in which the use of kinase
inhibitors should be prioritized. The evolving division of
NSCLCs into distinct actionable subtypes with mutually
exclusive driver oncogenes has helped usher the develop-
ment of small molecule tyrosine kinase inhibitors (TKIs) that
are now either clinically available or in early to late stage
development as palliative therapies in advanced NSCLC
(9-12).
This review focuses on EGFR mutated NSCLC and
provides an overview of the preclinical and clinical data
associated with the use of kinase inhibitors in this cohort of
lung cancers. The contents of this review were originally
presented at the Sa ˜ o Paulo School of Advanced Science
meeting entitled ‘‘Oncogenesis and Translational Medicine
forCancer Treatment’’(February 2014,Ribeira ˜ o Preto,SP,
Brazil) and expands topics covered in a recent review on
driver oncogenes in NSCLC (13).
EGFR
EGFR (alternatively named ErbB1 or HER1) is part of
the ErbB family of transmembrane receptor tyrosine kinases
involved in signal transduction pathways that regulate
proliferation and apoptosis (14). ErbB members exist as
monomers that dimerize in response to receptor-specific
ligands, such as amphiregulin and epidermal growth factor
(EGF), for EGFR. EGFR has an equilibrium that dictates its
ability to transition into inactive and active states (15,16),
with the latter allowing the transfer of a phosphate from
adenosine triphosphate (ATP) to a peptide substrate that
subsequently engages downstream signaling effectors
through downstream prosurvival and antiapoptotic targets
( 1 4 , 1 5 ) .T h ea c t i v eA T Pb i n d i n gs i t eo fE G F Rl i e si nt h ec l e f t
between the N-terminal and C-terminal lobes, within its
kinase domain (15,16).
EGFR mutations in NSCLC
EGFR mutations were initially reported in 2004 and
currently define the most prevalent actionable genomic-
ally classified subgroup of NSCLC (17-19). EGFR
mutations, pertinent to NSCLC, are spatially located
within the ATP binding site of the kinase (Figure 2A).
The most frequent EGFR mutations (Figure 2B) – –
commonly termed classic or sensitizing activating muta-
tions – – are in-frame deletions (around amino acid residues
747 to 750) of exon 19 (45% of EGFR mutations) and the
exon 21 L858R mutation (40% of EGFR mutations) (20).
The third most frequent class of EGFR mutations is
composed of in-frame insertions within exon 20 (5-10% of
EGFR mutations) of the kinase (21,22). Other recurrent
mutations include exon 18 point mutations in position
G719 (3% of EGFR mutations), the exon 21 L861Q
mutation (2% of EGFR mutations), and in-frame exon 19
insertions (,1% of EGFR mutations) (20,23). EGFR
mutations are more frequent in tumors with adenocarci-
noma histology, in never-smokers or light smokers, in
women with NSCLC, and in patients with East Asian
Figure 1. Pie chart of the frequency of driver oncogene mutations in lung adenocarcinomas from former/current smokers (left panel)
and from never-smokers (right panel). Note the striking difference between the higher frequency of EGFR, ALK, ROS1, ERBB2, RET,
BRAF (V600E), and NTRK1 mutations in never-smokers, and the higher frequency of KRAS mutations in smokers.
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patients with European or African ethnicities, 35% of
NSCLCs in East Asians, and 50% of NSCLCs in never-
smokers are EGFR mutation positive. The paucity of
classic EGFR mutations in tumors with squamous cell
carcinomas of the lung has led to the widespread
recommendation of obtaining the genotype (usually either
complete or allele-specific sequencing of key regions of
exons 18 to 21 of EGFR) only in nonsquamous NSCLCs,
except in cases with mixed histologies or with high clinical
suspicion (i.e., never-smokers). The College of American
Pathologists, International Association for the Study of
Lung Cancer, and Association for Molecular Pathology
recommend rapid testing for EGFR mutations and ALK
rearrangements in all patients with advanced-stage
adenocarcinoma (24). The etiology (environmental or
inherited) that underlies the initial genomic insult that
either leads to or selects for EGFR mutations in lung
tissues remains elusive. Interestingly, rare inherited
germline EGFR mutations (such as T790M and V843I)
can be genomic loci associated with an increased familial
clustering of EGFR mutated NSCLC, in which tumors
develop when a somatic classic EGFR mutation associ-
ates with the inherited allele (5,25).
Structural and biochemical characterization
of EGFR mutants in lung cancer
The crystal structures and enzymatic assays of some
EGFR mutations (such as L858R, G719S, T790M, and
D770_N771insNPG) have elucidated the mechanism of
activation and response to kinase inhibitors of these
mutants (16). As an example, EGFR-L858R shifts the
kinase equilibrium toward the active state (15,16,26), with
the mutated EGFR enhancing its homodimerization and
association with wild-type (WT) EGFR (27). In kinetic
models of L858R – – and also exon 19 deletion EGFR
mutated proteins – – one notes a decreased affinity for ATP
and enhanced affinity for EGFR TKIs compared to the WT
receptor (16). Hence, these mutations generate a wide
therapeutic window for EGFR TKIs in relation to WT
EGFR (16). In preclinical models, nanomolar concentra-
tions (i.e., concentrations that are 100 to 1000 times lower
than achievable serum concentrations) of gefitinib, erlo-
tinib, and afatinib are able to effectively inhibit classic
EGFR mutants while sparing the WT receptor (16). The
aforementioned change in affinity for ATP is one of the
hallmarks of oncogene kinase mutants that respond to
TKIs, and the EGFR TKI-resistant EGFR-T790M mutation
(as discussed later) is thought to increase EGFR affinity
for ATP as a mechanism of reducing the effectiveness of
inhibition by gefitinib or erlotinib (16,28). In contrast to
models for EGFR-L858R and exon 19 deletions/inser-
tions, the crystal structure and enzymatic assays for the
prototypical EGFR exon 20 insertion D770_N771insNPG
disclosed that this insertion locks the kinase’s C-helix in
its active position but with an EGFR TKI binding mode and
apparent affinity similar to that of WT EGFR (22). The
latter explains why the most prevalent EGFR exon 20
insertion mutations do not sensitize to available EGFR
TKIs. The atypical EGFR exon 20 insertion mutation
A763_Y764insFQEA possesses kinetics/structure that
more closely resembles EGFR-L858R and is therefore
an EGFR TKI-sensitizing mutation (22).
EGFR mutations, by favoring the active kinase state,
are oncogenic in NSCLC cell lines, mouse models, and
human tumors. They do this by inducing EGFR-mediated
antiapoptotic and prosurvival proteins via downstream
Figure 2. Epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC). A, Structure of the kinase
domain of EGFR in complex with erlotinib (based on Protein Data Bank [PDB] accession code 1M17) and location of the most common
EGFR mutations. B, Frequency, exon location, and sensitivity to EGFR inhibitors of the most common EGFR mutations. TKIs: tyrosine
kinase inhibitors.
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extracellular-signal-regulated kinase, janus kinase/signal
transducer and activator of transcription, and phosphati-
dylinositol-3-kinase/protein kinase B cascades (14).
These signaling networks make cells with EGFR muta-
tions dependent on this ErbB member for their survival
(Figure 3A). EGFR mutant inhibition leads to upregulation
and activation of proapoptotic molecules that initiate the
intrinsic mitochondrial apoptotic pathway by affecting the
balance of pro- vs antiapoptotic BCL-2 family members.
The most well-described apoptotic signal induced by
EGFR inhibition is that of the BH3 domain-only molecule
BIM (Figure 3A), which in the mitochondria binds to
antiapoptotic BCL-2 members and antagonizes their
antiapoptotic activity (29). Therefore, the apoptotic
response induced by EGFR TKIs defines an oncogene-
addicted model.
Clinical data on EGFR TKIs for EGFR
mutated NSCLC and approval of gefitinib,
erlotinib, and afatinib
Gefitinib and erlotinib, oral reversible EGFR TKIs, were
approved for the treatment of unselected NSCLC prior to
the information on EGFR mutations as predictive biomar-
kers for EGFR TKIs (30,31). Both erlotinib and gefitinib
were also tested in combination with platinum-based
chemotherapies, and no improvement in response or
survival was demonstrated (30,31). The limited activity of
these TKIs in non-EGFR genotyped, or unselected,
NSCLCs, is mostly clear when EGFR mutation status is
obtained. The response rate (RR) of EGFR WT tumors
(many harboring other driver oncogene alterations) is
below 2% with 250 mg daily gefitinib (10), and in
randomized trials that restrict enrollment to EGFR WT-
bearing NSCLCs, the traditional cytotoxic single agent
docetaxel produces superior RR, progression-free survival
(PFS), and overall survival (OS) than 150 mg daily erlotinib
(32). Therefore, the use of EGFR TKIs in tumors without an
EGFR sensitizing mutation leads to minimal clinical
benefits in most cases and has fallen out of favor.
EGFR TKIs (gefitinib, erlotinib, and afatinib) lead to
responses in most patients with advanced NSCLCs
harboring sensitizing EGFR activating mutations when
given as first or further lines of treatment. In the late 2000s
and early 2010s, randomized studies confirmed the
predictive value of classic EGFR mutations as the major
biomarkers for the beneficial effects of gefitinib (10,33),
erlotinib (11), and afatinib (12). It is important to note that
the most predominant somatic mutations that were
included in these trials were EGFR exon 19 deletions
(the most common is delE746_A750) and L858R; there-
fore, all current genomic-based approvals for EGFR TKIs
are limited to tumors with the aforementioned classic
Figure 3. A, Mechanism of activation of the JAK/STAT, MAPK/ERK and PI3K/AKT pathways by epidermal growth factor receptor
(EGFR) mutations and their inhibition by EGFR tyrosine kinase inhibitors (TKIs). B, Mechanisms of acquired resistance to EGFR TKIs
in EGFR mutated non-small-cell lung cancer (NSCLC) with emphasis on the EGFR-T790M resistant mutation and oncogene bypass
tracks that re-activate downstream signaling cascades.
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randomized phase III trials that specifically compared an
EGFR TKI against systemic platinum-based chemothera-
pies in the first-line setting of advanced NSCLC (34).
These include IPASS (10), First-SIGNAL (35), WJTOG
3405 (36), NEJ002 (37), OPTIMAL (38), EURTAC (11),
Lux-LUNG 3 (12), and Lux-LUNG 6 (39). Table 1 shows
PFS, RR, and OS for these trials. In all trials, the RR with
the EGFR TKI was nearly double (if not more) that of a
diverse array of platinum-doublets and the PFS times
were significantly longer (in most trials it exceed a median
of 9 months for the EGFR TKI). It is interesting to note that
most of these trials were not designed to, and did not,
demonstrate an improvement in survival with the initial
use of an EGFR TKI compared to cytotoxic chemother-
apy, data that can be explained by the very high rate of
cross-over from the chemotherapy to the EGFR TKI (10-
12). In all of the trials, quality of life parameters were
significantly superior with the EGFR TKI (10-12). The
summation of information available indicates that EGFR
TKIs are the most robust initial therapy for NSCLCs with
EGFR exon 19 deletions or L858R.
Gefitinib, erlotinib, and afatinib have approval labels
indicating that their use should be restricted to the first-line
treatment of NSCLCs harboring the aforementioned classic
EGFR mutations. These recommendations are now part of
evidence-based practice guidelines for the care of patients
with NSCLC (40,41) and have made the EGFR genotype of
nonsquamous NSCLC ubiquitous for the day-to-day clinical
care of advanced NSCLC (24). The concurrent use of
platinum-doublet chemotherapy (carboplatin plus paclitaxel)
with erlotinib was not superior to erlotinib alone in the
management of never-smokers and light smokers with
EGFR mutated tumors (42), and current clinical guidelines
only recommend use of EGFR TKI monotherapy in TKI-
naive patients (41). Gefitinib, erlotinib, and afatinib have not
been compared head-to-head in well-designed clinical trials,
and it is not known whether one EGFR TKI is superior to the
other in terms of anticancer control and tolerability.
The management of NSCLCs that have rarer EGFR
TKI-sensitizing mutations is controversial, and most data
have been obtained from retrospective series. One useful
resource that can be used as a comprehensive catalog of
tumor gene-drug response outcomes from individual
patients with less common EGFR mutations or compound
(i.e., complex or double) mutations is the DNA-mutation
Inventory to Refine and Enhance Cancer Treatment
(DIRECT) database (43) hosted by Vanderbilt University
(http://www.mycancergenome.org/about/direct). NSCLCs
with EGFR-G719A (or C, or S), L861Q, exon 19
insertions, and the exon 20 A763_Y764insFQEA respond
to gefitinib, erlotinib and afatinib (43). Retrospective
cohorts have also confirmed that nonsensitizing EGFR
mutations in preclinical models, in specific EGFR exon 20
in-frame insertion mutations (such as V769_D770insASV
and D770_N771insSVD), are associated with primary
progressive disease to EGFR TKIs (gefitinib, erlotinib,
and afatinib) in patients whose NSCLCs harbor these
mutations (21,22,41,44).
The use of gefitinib, erlotinib, and afatinib iscomplicated
Table 1. Clinical trials of gefitinib, erlotinib and afatinib against platinum-doublet chemotherapy as first line therapy for advanced EGFR
mutated NSCLC.
Trial (reference)
[no. patients/drug]
RR (RECIST) PFS (months) OS (months)
EGFR
TKI
Platinum-
doublet
P EGFR
TKI
Platinum-
doublet
HR (P) EGFR
TKI
Platinum-
doublet
HR (P)
IPASS (10,33)
[437/gefitinib]
71.2% 47.3% ,0.001 9.5 6.3 0.48
(,0.001)
21.6 21.9 1
(0.99)
NEJ002 (37)
[230/gefitinib]
73.7% 30.7% ,0.001 10.8 5.4 0.30
(,0.001)
30.5 23.6 NR
(0.31)
WJTOG 3405 (36)
[177/gefitinib]
62.1% 32.2% ,0.001 9.2 6.3 0.49
(,0.001)
30.9 not
reached
1.64
(0.21)
OPTIMAL (38)
[154/erlotinib]
83% 36% ,0.001 13.1 4.6 0.16
(,0.001)
22.6 28.8 1.06
(0.68)
EURTAC (11)
[173/erlotinib]
58% 15% ,0.001 9.7 5.2 0.37
(,0.001)
19.3 19.5 1.04
(0.87)
LUX-Lung 3 (12)
[345/afatinib]
56% 23% 0.001 11.1 6.9 0.58
(,0.001)
NR NR 1.12
(0.60)
LUX-Lung 6 (39)
[366/afatinib]
66.9% 23% ,0.001 11 5.6 0.28
(,0.001)
22.1 22.2 0.95
(0.76)
EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor; NSCLC: non-small-cell lung cancer; RR: response rate; PFS:
progression-free survival; OS: overall survival; RECIST: response evaluation criteria in solid tumors; ref: reference, HR: hazard ratio;
NR: not reported. Differences in RR were calculated by each publication using Fisher’s exact test. The HR was calculated by each
publication using Cox regression analysis and differences in PFS compared using the log-rank test.
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cutaneous, mucosal, and gastrointestinal adverse events
associated with EGFR TKIs. At the current recommended
starting dose of these agents (250 mg daily of gefitinib,
150 mg daily of erlotinib, and 40 mg daily of afatinib), most
patients will have skin toxicities. The rash can be minimal,
and managed with topical agents, or severe, requiring dose
reductions (10-12). Afatinib is associated with a higher
incidence of cutaneous and oral (mucositis) adverse events
– which likely reflect the irreversible binding of WT EGFR in
noncancerous tissues – – than gefitinib or erlotinib (10-12). It
is well known that dose reductions of gefitinib and erlotinib
can ameliorate symptoms, without affecting efficacy, in
most patients with EGFR mutated NSCLC. Indeed, doses
as low as 25 mg daily (which is far lower than the label
starting dose of 150 mg daily) of erlotinib or 250 mg of
gefitinib every other day have been associated with
prolonged responses with minimal toxicities (45,46).
Preclinical models and clinical trials to determine the most
appropriate ‘‘biologically effective’’ dose of EGFR TKIs (if
daily dosing, pulsatile doses, or combinations) may in the
future change the current paradigm of initial daily dosing of
gefitinib, erlotinib, and afatinib (47).
Resistance to EGFR inhibitors in EGFR
mutated NSCLC
The main limitation of the widespread benefits of
EGFR TKIs is the development of acquired resistance in
patients with EGFR mutated NSCLC treated with this
class of drugs. Resistant mutations (i.e., EGFR-T790M)
that disrupt kinase-drug binding contacts and activation of
shared downstream signaling pathways through other
aberrant kinases (i.e., ‘‘bypass tracks’’ or ‘‘oncogene
kinase co-dependence states’’) are the predominant
models for acquired resistance (Figure 3B) under pres-
sure of a TKI in preclinical models and clinical samples
(48-52). A simple consensus clinical criterion that defines
acquired resistance (previous treatment with EGFR TKI,
tumor with EGFR sensitizing mutation and systemic
progression while on TKI) has been loosely used for
clinical trial development (53).
The first identified, and most common, mechanism of
acquired resistance is the EGFR-T790M mutation located
at the gatekeeper amino acid residue (49,50). This
genomic event is present in ,60-65% of cases with
acquired resistance to the first-generation (gefitinib and
erlotinib) EGFR TKIs and is also present with acquired
resistance to second-generation (afatinib) EGFR TKIs
(48,54,55). This genomic mutation may be acquired and
then selected for during TKI therapy or, more likely, EGFR-
T790M clones may already exist in the heterogeneous bulk
of an EGFR mutated TKI-sensitive NSCLC and then are
selected for during TKI therapy (48,54,55). The T790M
mutation at the gatekeeper position of the ATP kinase
pocket is capable of annulling the sensitization of activating
mutations (16,28). EGFR-T790M-bearing NSCLCs with
acquired resistance to gefitinib or erlotinib do not respond
to the second-generation EGFR TKI afatinib. The latter
may be explained by the inability of this irreversible TKI to
generate an effective clinical therapeutical window that can
deter T790M and not inhibit WT EGFR (56,57). The dual
inhibition of EGFR with a monoclonal antibody (cetuximab)
and the irreversible TKI afatinib has some activity in
NSCLC patients with acquired resistance to EGFR TKIs
(48,56). However, this strategy is associated with major
cutaneous adverse events (48) that may affect the ability of
this schemetomove forwardin randomizedtrials.Covalent
pyrimidine inhibitors of EGFR-T790M (i.e., third-generation
EGFR TKIs) have been developed (58-60), and these
drugs are more potent against EGFR-T790M and less
potent against WT EGFR than first- or second-generation
EGFR TKIs (58). The compounds in early-stage clinical
development are named AZD9291 (55) and CO-1686 (60).
Initial results of the phase I clinical trials of these drugs
[AZD9291 (AURA series) and CO-1686 (TIGER series)]
have already shown responses (RRs that exceed 60%) in
tumors harboring EGFR-T790M (55,61). Registration of
phase II and III trials has commenced for both of these
compounds, and the Thoracic Oncology community
expects that at least one drug will be approved for use in
EGFR mutated NSCLC within the next few years.
Bypass signaling tracks as mechanisms of acquired
resistance to EGFR TKIs are more varied (Figure 3B).
The validated oncogenes that participate in these bypass
mechanisms comprise hepatocyte growth factor receptor
(MET) (51,52,62), ERBB2 (63), and others (48,54,55).
These changes are individually uncommon (with a
frequency of less than 15%), and they can be co-identified
with the gatekeeper EGFR-T790M change in the same
specimen (48,54,55). Successful treatments for these
bypass tracks await clinical trials (55). Some (,5%)
biopsies of NSCLCs with acquired resistance to first-
generation EGFR TKIs show histological transformation
to poorly differentiated neuroendocrine tumors (52). This
proposed transformation to small-cell lung cancer may be
mediated in part by activation of pathways that alter the
stem cell potential of the TKI-resistant cell (48,54,55).
The selection for and loss of mechanisms of resistance
have been noted in patients from whom multiple biopsies
were taken during periods on or off an EGFR TKI (52),
adding to the involvedness on how to manage resistance.
The current clinical management of patients with
acquired resistance to EGFR TKIs remains undetermined
owing to the complexity of mechanisms of resistance and
the lack of mature trials using EGFR-T790M-specific
inhibitors. Therefore, most of the clinical experience in this
setting is dictated by retrospective series and extrapola-
tion of preclinical data. In patients not qualified for clinical
trials, the algorithm for treatment decisions depends
on the sites of symptomatic progression and individual
patient characteristics. Multiple groups have reported on
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oligoprogression), in which the central nervous system
(CNS) or other extra-CNS sites may be the main locations
of progression (64). In sites such as the brain and bone,
local therapy options (surgical or radiotherapy) may allow
for continuation of the EGFR TKI as monotherapy for an
extended period prior to more widespread systemic
progression (64). In many instances of asymptomatic
radiographic progression, the continued use of EGFR TKI
monotherapy can prevent the flaring of clinically signifi-
cant disease (48,54,55). The latter may represent
uncontrolled growth of TKI-sensitive subclones of the
heterogeneous tumor. Eventually, widespread sympto-
matic progression develops for available EGFR TKIs.
Most oncologists have advocated enrollment in clinical
trials (that evaluate the aforementioned precision thera-
pies for mechanisms of resistance) or the use of
evidence-based cytotoxic chemotherapies (41) for the
NSCLC line of therapy in question [i.e., a platinum-doublet
for a patient that is chemotherapy naive and single-agent
chemotherapy (docetaxel or pemetrexed) for patients who
have already received platinum-doublets]. How the use of
continued EGFR TKIs in combination with chemotherapy
alters clinical outcomes in this population requires well-
conducted clinical trials for a robust answer. A retro-
spective case series matched this strategy to the use of
chemotherapy alone and disclosed an improvement in RR
but not in other survival parameters (65). Owing to the
observed cases of disease flare and the preclinical model
that continued inhibition of TKI-sensitive clones is
beneficial (47,48), many oncologists continue the toler-
ated dose of the EGFR TKI in addition to cytotoxic
chemotherapies. Clinical trials and evidence-based guide-
lines for the management of EGFR mutated NSCLCs with
acquired resistance to gefitinib, erlotinib, afatinib, and
other EGFR TKIs are eagerly awaited.
Ongoing and future research efforts on
EGFR mutated NSCLC
Despite the unprecedented knowledge garnered over
the last decade on EGFR mutant biology and on clinical
care of EGFR mutated NSCLC with TKIs, many questions
remain unanswered. Below we add important questions
that should be addressed.
1) What is the role of EGFR TKIs for early stage and
locally advanced EGFR mutated NSCLCs? It is possible
to speculate that the use of first- and second-generation
EGFR TKIs may indeed augment ‘‘cure’’ rates attained
with surgery/radiotherapy, or at least significantly delay
recurrences when the tumor burden is lower (disease
stages I-III). Some retrospective studies have demon-
strated discrete improvements in the adjuvant setting use
of gefitinib or erlotinib (66). Ongoing prospective and
randomized trials are evaluating the role of neoadjuvant or
adjuvant gefitinib, erlotinib, and afatinib in the care of
patients with stages I-III EGFR mutated NSCLC.
2) What is the most effective biological dosing scheme
for EGFR TKIs? Most current EGFR TKIs are used at
their maximum tolerated dose in a daily dosing fashion
(67). However, innovative preclinical modeling studies
have demonstrated that combinations of less-toxic dosing
schemes with intermittent pulsatile dosing periods may be
a more rational treatment approach (47). Clinical trials
using alternative dosing schemes are under way.
3) Which approved EGFR TKI (gefitinib, erlotinib, or
afatinib) should be used for NSCLCs with EGFR-L858R or
exon 19 deletions, and for NSCLCs with less frequent
EGFR mutations (G719X, exon 19 insertions, L861Q, and
others)? These are difficult clinical questions that will
require significant commitment from clinical trials [some
ongoing trials are comparing afatinib (second-generation)
to gefitinib/erlotinib (first-generation EGFR TKIs) for
NSCLCs with EGFR-L858R or exon 19 deletions] and
may eventually hinder not only the efficacy of a given TKI,
but also its toxicity profile, cost, and resource implemen-
tation by health care system organizations.
4) Should an EGFR TKI be developed for EGFR exon
20 insertion mutants? As described previously, EGFR
exon 20 insertion mutants [the third most common class
of EGFR mutations (Figure 2B)] are a unique class of
activating EGFR mutations that do not have a therapeutic
window for use of first-, second-, or third-generation
EGFR TKIs compared to WT EGFR (21,22). Therefore,
the development of novel classes of EGFR TKIs and/or
alternative treatment schedules of available TKIs (that
may inhibit EGFR exon 20 insertions and allow for only
intermittent exposure of WT EGFR) is an unmet clinical
need for EGFR exon 20 insertion mutated NSCLC.
Different strategies of care, including use of cytotoxic
chemotherapies and biological compounds, are also
undergoing clinical trial evaluation for these specific
EGFR mutated NSCLCs.
5) What is the role of continuing the original EGFR TKI
after radiographic progression on therapy? As detailed
above, this question is undergoing detailed clinical trial
evaluation, and we should have an answer within the next
few years on the benefits of continued EGFR inhibition in
the presence of acquired resistance to gefitinib, erlotinib,
and afatinib.
6) Which third-generation EGFR TKI is most effective
against EGFR-T790M, and what should the Thoracic
Oncology community and regulatory agencies tolerate as
a registration strategy (RR, PFS, randomized trials
against cytotoxic agents)? The clinical development of
the covalent pyrimidine inhibitors of EGFR-T790M – –
AZD9291 and CO-1686 – – is an important advance for
the therapy of acquired resistance to first- and second-
generation EGFR TKIs mediated by EGFR-T790M (55).
The ongoing AURA (for AZD9291) and TIGER (for CO-
1686) series of phase II and III trials should be able to
determine whether these compounds will be approved
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7) What is the role of treatment combinations to delay
or prevent acquired resistance to EGFR TKIs in EGFR
mutated NSCLC? The true maximization of the clinical
benefits of EGFR TKIs for EGFR mutated NSCLC will
only occur when therapies can delay or prevent the
development of biological mechanisms of resistance
(Figure 3B). As more knowledge is acquired on the
possible mechanisms of tumor resistance to first-,
second-, and third-generation EGFR TKIs and on
innovative treatment schedules for kinase inhibitors
(48,54,55), the field can foresee the development of
clinical strategies that will incorporate multiple inhibitors of
EGFR and of bypass signals to provide long-term disease
control for these recalcitrant tumors.
Conclusions
Somatic TKI-sensitizing EGFR mutations are the most
robust predictive biomarkers for symptom improvement,
radiographic response, and increments in PFS when
EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for
patients with advanced NSCLC. However, the palliative
benefits and increments in survival that EGFR TKIs afford
are limited by multiple biological mechanisms of tumor
adaptation or resistance. Future efforts toward delaying,
preventing, and treating resistance hold the promise to
boost the median survival of patients with EGFR mutated
NSCLC.
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